Publications by authors named "P Moayyedi"
Background: Many patients diagnosed with gastro-oesophageal reflux disease (GERD) have persistent symptoms despite proton pump inhibitor (PPI) therapy.
Aims: The aim of this consensus is to provide evidence-based statements to guide clinicians caring for patients with refractory reflux-like symptoms (rRLS) or refractory GERD.
Methods: This consensus was developed by the International Working Group for the Classification of Oesophagitis.
Article Synopsis
- Fecal microbiota transplantation (FMT) was evaluated for its ability to induce remission in Crohn's disease (CD) in a double-blind study, marking the first investigation of its kind.
- The study involved 21 patients receiving FMT and 13 receiving a placebo, and was terminated early due to futility, showing no significant difference in remission rates between groups at week 8.
- While FMT did not improve clinical outcomes, both groups reported improvements in health-related quality of life; future research may explore alternative strategies to boost treatment efficacy.
Introduction: Digital health tools can be beneficial in the care of patients with chronic conditions and have the potential for widespread impact as readily scalable and cost-effective health interventions. However, benefits are often contingent on users sustaining their engagement with these tools over time. Sustained engagement with digital health tools can be challenging, and high rates of attrition from digital interventions are common.
View Article and Find Full Text PDFClinical Question: In adult patients with inflammatory bowel disease, inflammatory arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis), or psoriasis taking biologic drugs, does proactive therapeutic drug monitoring (TDM) improve outcomes as compared with standard care?
Context And Current Practice: Standard care for immune mediated inflammatory diseases includes prescribing biologic drugs at pre-determined doses. Dosing may be adjusted reactively, for example with increased disease activity. In proactive TDM, serum drug levels and anti-drug antibodies are measured irrespective of disease activity, and the drug dosing is adjusted to achieve target serum drug levels, usually within pre-specified therapeutic ranges.